Brit Creelman, PhD
Licensed Clinical Psychologist
Evanston IL
As a therapist, my intention is to offer a space where clients can safely explore the behaviors and beliefs that may be creating roadblocks in their lives—inviting the possibility of seeing these patterns in a new light. From a more spacious perspective, acceptance can begin to settle in, allowing for a more direct and grounded connection with the present moment. I’m especially comfortable doing “parts work” through an Internal Family Systems (IFS) lens, and may be a particularly good fit for individuals with an established mindfulness practice and a capacity to tune into their inner experience.
My orientation to working with psychedelics in the clinical trial space is rooted in a “set and setting” approach. This includes thoughtful preparation and intention-setting prior to dosing; ensuring psychological safety and support throughout the journey; and post-session integration to help consolidate, embody, and apply the insights that emerge. This model draws from ancient indigenous healing traditions and is supported by decades of research into the therapeutic potential of expanded states of consciousness for conditions such as depression and PTSD.
Brit Creelman, PhD, is a clinical psychologist whose career has spanned a wide range of community-based and trauma-informed work. His experience includes providing alternatives to psychiatric hospitalization, engaging in peace and justice activism in war zones, conducting research on the relationship between trauma and substance use, and offering home visits in public housing communities. For over a decade, he served as the training director for a program supporting youth survivors of complex trauma. Currently, Dr. Creelman maintains a private practice in Evanston, IL, and contributes to the Internal Family Systems (IFS) Institute by assisting with trainings—including Level 1 program for providers of psychedelic-assisted therapy.
In the field of psychedelic research, Dr. Creelman is involved in two Phase 3 clinical trials investigating psilocybin for depression: the Usona study (PSIL301) and the global Compass Pathways study (COMP360). Previously, he served as Lead Dosing Session Monitor in MindMed’s Phase 2 study exploring LSD for anxiety, and as Lead Facilitator in Usona’s PSIL201 Phase 2 study on psilocybin for depression. Favorable results from PSIL201 were published in the Journal of the American Medical Association (JAMA, August 2023). The MindMed trial was a historic milestone, marking the first legal administration of LSD in the U.S. since psychedelic research was shut down in the 1970s. Dr. Creelman received training through the Usona Institute, with instructional support from the California Institute of Integral Studies (CIIS), and he continues to consult with leading clinicians in the psychedelic research field. He has also worked in ceremonial settings, including at Atman Retreat in Jamaica, supporting psycho-spiritual healing through plant medicine.
I enjoy providing preparation and integration support for those who seek out expanded states of consciousness experience, such as through breathwork retreats and international cerimonial experiences. I also enjoy providing consultation to IFS therapists who are curious about integrating IFS and psychedelic assisted therapy.